

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Roskamp, et al

Examiner: Khanna, Hemant

Art Unit: 1654

Application No.: **10/757,201**

Filed: **January 14, 2004**

Title: **Method For Reducing Cardiovascular
Morbidity and mortality in Prediabetic
Patients and Patients With Type 2
Diabetes**

Response to the Restriction Requirement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sir:

This paper is responsive to the Restriction Requirement mailed on 10/3/06.

Per Examiner's request, Applicant herein elects, without traverse, to prosecute the claims of Group I (i.e. Claims 1-7, 15-33 drawn to treating IGT and Type II diabetes).

Applicants affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

Respectfully submitted,



Barbara E. Kurys, Reg. No.: 34,650
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-2965
Telefax: 908-231-2626

sanofi-aventis Docket No. USAV2003-0012 US NP